Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Jianzhong Shou"'
Autor:
Xinxin Zhang, Yichen Wang, Yilin Wang, Jie Zhang, Jin Zhang, Lianyu Zhang, Sicong Wang, Jianzhong Shou, Yan Chen, Xinming Zhao
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background The Vesical Imaging-Reporting and Data System (VI-RADS) has demonstrated effectiveness in predicting muscle invasion in bladder cancer before treatment. The urgent need currently is to evaluate the muscle invasion status after neo
Externí odkaz:
https://doaj.org/article/a880bd6c2c3c418aad5b43b20ba50e4b
Autor:
Ruiyang Xie, Bingqing Shang, Hongzhe Shi, Xingang Bi, Yan Song, Wang Qu, Hongsong Bai, Linjun Hu, Jie Wu, Honglei Cui, Gan Du, Lei Guo, Shan Zheng, Jianming Ying, Changling Li, Jianhui Ma, Aiping Zhou, Jianzhong Shou
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21807-21819 (2023)
Abstract Background The efficacy of systemic therapy regimens, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (IO‐TKI) and targeted therapy, for metastatic clear cell renal cell carcinoma (ccRCC) remains unpredictable due to th
Externí odkaz:
https://doaj.org/article/c363eff574ea4eaa8124c12a23691c7e
Autor:
Gan Du, Zhichao Jiang, Wang Qu, Jin Zhang, Shan Zheng, Yueping Liu, Aiping Zhou, Hongzhe Shi, Jianzhong Shou
Publikováno v:
Heliyon, Vol 10, Iss 6, Pp e27685- (2024)
Background: The study of bladder preservation for muscle-invasive bladder cancer (MIBC) mainly focuses on the T2 stage, which remains difficult in the T3 and T4 stage. Pembrolizumab has been applied as neoadjuvant therapy followed by radical cystecto
Externí odkaz:
https://doaj.org/article/33d79814b50a4813bdd2198c2e9734a6
Autor:
Ruiyang Xie, Jie Wu, Bingqing Shang, Xingang Bi, Weixing Jiang, Chuanzhen Cao, Aiping Zhou, Hongzhe Shi, Jianzhong Shou
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7051-7064 (2023)
Abstract Objective For patients with advanced or metastatic renal cell carcinoma (RCC), the dose of targeted agents was recommended in combination with immune checkpoint inhibitors. We performed a network meta‐analysis to describe a categorized saf
Externí odkaz:
https://doaj.org/article/1b842f11f30749e69352ad226b69c509
Autor:
Bingqing Shang, Honglei Cui, Ruiyang Xie, Jie Wu, Hongzhe Shi, Xingang Bi, Lin Feng, Jianzhong Shou
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-15 (2023)
Abstract In addition to the anti-infection response, neutrophils are linked to tumor progression through the secretion of inflammation components and neutrophil extracellular traps (NETs) formation. NET is a web-like structure constituted by a chroma
Externí odkaz:
https://doaj.org/article/80d6eed4f38b426ca66e7bf728426fa4
Autor:
Ruiyang Xie, Jie Wu, Bingqing Shang, Xingang Bi, Chuanzhen Cao, Youyan Guan, Hongzhe Shi, Jianzhong Shou
Publikováno v:
Cancer Innovation, Vol 1, Iss 4, Pp 293-304 (2022)
Abstract Background By prolonging overall survival and reducing disease recurrence rates, immune checkpoint inhibitors (ICIs) are an emerging adjuvant therapy option for patients with resectable malignant tumors. However, the safety profile (deaths a
Externí odkaz:
https://doaj.org/article/6e0138c8b8064055af97dcbd442909a1
Autor:
Yuxiang Zhang, Na Hong, Sida Huang, Jie Wu, Jianwei Gao, Zheng Xu, Fubo Zhang, Shaohui Ma, Ye Liu, Peiyuan Sun, Yanping Tang, Chun Liu, Jianzhong Shou, Meng Chen
Publikováno v:
Cancer Innovation, Vol 1, Iss 2, Pp 124-134 (2022)
Abstract Background Kidney cancer originates from the urinary tubule epithelial system of the renal parenchyma, accounting for 20% of all urinary system tumors. Approximately 70% of cases are localized at diagnosis, and 30% are metastatic. Most local
Externí odkaz:
https://doaj.org/article/fe15dbfd9d9248e8ab29f1d215290b5f
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Objective To investigate the efficacy and complications of surgical treatment in patients with renal cell carcinoma aged ≥ 75 years. Methods From January 2009 to May 2019, we assessed 166 patients aged 75 years and older, who either had ra
Externí odkaz:
https://doaj.org/article/3d9be1baa73b424e8f9179d521b764dc
Autor:
Caifeng Gong, Wen Zhang, Yongkun Sun, Jianzhong Shou, Zhichao Jiang, Tianyi Liu, Shengzhou Wang, Jun Liu, Ying Sun, Aiping Zhou
Publikováno v:
iScience, Vol 26, Iss 6, Pp 106720- (2023)
Summary: The immune-genetic changes that occur in cancer patients experiencing hyperprogressive disease (HPD) during combined immunotherapy are unclear. In this study, HPD patients with pre- and post-HPD samples and non-HPD patients with solid tumors
Externí odkaz:
https://doaj.org/article/18543e42d8124c869461fbd170d8aaf2
Autor:
Hongzhe Shi, Chuanzhen Cao, Li Wen, Lianyu Zhang, Jin Zhang, Jianhui Ma, Jianzhong Shou, Changling Li
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Several models and markers were developed and found to predict outcome of advanced renal cell carcinoma. This study aimed to evaluate the prognostic value of the ratio of maximum to minimum tumor diameter (ROD) in metastatic clear
Externí odkaz:
https://doaj.org/article/55e7318f2747400082be739c359bbd25